This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced
ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel.
The primary objective of this study is to determine the recommended phase II dose (RP2D) of
Artemisia annua.